SECOND AMENDMENT TO THE DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • November 9th, 2021 • Pulmatrix, Inc. • Pharmaceutical preparations
This Second amendment to the Development and Commercialization Agreement (“Second Amendment”) is entered into as of 8 November, 2021 (the “Effective Date”) and amends the Development and Commercialization entered into on April 15, 2019 (as amended by the parties on May 3, 2019, “Agreement”) between, Pulmatrix, Inc. a company incorporated under the laws of the State of Delaware, and Pulmatrix Operating Company, Inc., a company incorporated under the laws of the State of Delaware (together “Company”), and each having a principal place of business at 99 Hayden Avenue, Suite 390, Lexington, Massachusetts 02421, and Cipla Technologies, LLC, a limited liability company organized under the laws of Delaware, and having a principal place of business at 7 Oser Avenue, Hauppauge, NY 11788 (“Cipla”). Company and Cipla may be referred to herein as a “Party” and collectively as the “Parties”. Capitalized terms used herein but not otherwise defined herein shall have the respective meanings given such
